Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 393-403

  Chun, Jaemoo ^a   Li, Rui Juan ^b   Cheng, Mao Sheng ^b   Kim, Yeong Shik ^a  

^a Seoul National University   (South Korea)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alantolactone; MDA MB 231 cells; Sesquiterpene lactone; STAT3; Triple negative breast cancer (TNBC)

Indexed keywords

ALANTOLACTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; TYROSINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; LACTONE; SESQUITERPENE; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERLEUKIN-6; LACTONES; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; SESQUITERPENES, EUDESMANE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84920569103     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.049     Document Type: Article

References (35)

1. Abubaker K., Luwor R.B., Escalona R., McNally O., Quinn M.A., Thompson E.W., et al. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front. Oncol 2014, 4:75.
2. Vitale G., Zappavigna S., Marra M., Dicitore A., Meschini S., Condello M., et al. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol. Adv 2012, 30:169-184.
3. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
4. Kim S.R., Seo H.S., Choi H.S., Cho S.G., Kim Y.K., Hong E.H., et al. Trichosanthes kirilowii ethanol extract and cucurbitacin D inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. Evid. Based Complement. Alternat. Med 2013, 2013:975350.
5. Walker S.R., Xiang M., Frank D.A. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol. Cell. Endocrinol 2014, 382:616-621.
6. Marotta L.L., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Invest 2011, 121:2723-2735.
7. Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur. J. Cancer 2010, 46:1223-1231.
8. Lee H.J., Seo N.J., Jeong S.J., Park Y., Jung D.B., Koh W., et al. Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition. Carcinogenesis 2011, 32:804-811.
9. De Laurentiis M., Cianniello D., Caputo R., Stanzione B., Arpino G., Cinieri S., et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat. Rev 2010, 36:S80-S86.
10. Podolak I., Galanty A., Sobolewska D. Saponins as cytotoxic agents: a review. Phytochem. Rev 2010, 9:425-474.
11. Rivat C., Rodrigues S., Bruyneel E., Pietu G., Robert A., Redeuilh G., et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) - and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 2005, 65:195-202.
12. Zhao M., Jiang B., Gao F.H. Small molecule inhibitors of STAT3 for cancer therapy. Curr. Med. Chem 2011, 18:4012-4018.
13. Yu Z.Y., Huang R., Xiao H., Sun W.F., Shan Y.J., Wang B., et al. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3. Int. J. Cancer 2010, 127:1259-1270.
14. Chun J., Choi R.J., Khan S., Lee D.S., Kim Y.C., Nam Y.J., et al. Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. Int. Immunopharmacol 2012, 14:375-383.
15. Mi X.G., Song Z.B., Wu P., Zhang Y.W., Sun L.G., Bao Y.L., et al. Alantolactone induces cell apoptosis partially through down-regulation of testes-specific protease 50 expression. Toxicol. Lett 2014, 224:349-355.
16. Chun J., Joo E.J., Kang M., Kim Y.S. Platycodin D induces anoikis and caspase-mediated apoptosis via p38 MAPK in AGS human gastric cancer cells. J. Cell. Biochem 2013, 114:456-470.
17. Chun J., Kim Y.S. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chem. Biol. Interact 2013, 205:212-221.
18. Pandey M.K., Sung B., Aggarwal B.B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int. J. Cancer 2010, 127:282-292.
19. Lakkaraju A.K., van der Goot F.G. Calnexin controls the STAT3-mediated transcriptional response to EGF. Mol. Cell 2013, 51:386-396.
20. Kim B.H., Won C., Lee Y.H., Choi J.S., Noh K.H., Han S., et al. Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs. Biochem. Pharmacol 2013, 86:950-959.
21. Nair R.R., Tolentino J.H., Hazlehurst L.A. Role of STAT3 in transformation and drug resistance in CML. Front. Oncol 2012, 2:30.
22. Gariboldi M.B., Ravizza R., Molteni R., Osella D., Gabano E., Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 2007, 258:181-188.
23. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol 2012, 41:1181-1191.
24. Souissi I., Najjar I., Ah-Koon L., Schischmanoff P.O., Lesage D., Le Coquil S., et al. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB. BMC Cell Biol 2011, 12:14.
25. Quesnelle K.M., Boehm A.L., Grandis J.R. STAT-mediated EGFR signaling in cancer. J. Cell. Biochem 2007, 102:311-319.
26. Zhang X., Yue P., Page B.D., Li T., Zhao W., Namanja A.T., et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9623-9628.
27. Caraglia M., Vitale G., Marra M., Budillon A., Tagliaferri P., Abbruzzese A. Alpha-interferon and its effects on signalling pathways within cells. Curr. Protein Pept. Sci 2004, 5:475-485.
28. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann. N. Y. Acad. Sci 2009, 1171:59-76.
29. Burshtyn D.N., Yang W., Yi T., Long E.O. A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1. J. Biol. Chem 1997, 272:13066-13072.
30. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res 2006, 12:20-28.
31. Barre B., Vigneron A., Perkins N., Roninson I.B., Gamelin E., Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med 2007, 13:4-11.
32. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009, 15:283-293.
33. Saha A., Blando J., Silver E., Beltran L., Sessler J., DiGiovanni J. 6-Shogaol from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo through inhibition of STAT3 and NF-κB signaling. Cancer Prev. Res. (Phila.) 2014, 7:627-638.
34. Mackenzie G.G., Queisser N., Wolfson M.L., Fraga C.G., Adamo A.M., Oteiza P.I. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-κB and STAT3 pathways in Hodgkin's lymphoma cells. Int. J. Cancer 2008, 123:56-65.
35. Sethi G., Chatterjee S., Rajendran P., Li F., Shanmugam M.K., Wong K.F., et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol. Cancer 2014, 13:66.